Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 7, Issue 7, Pages 929-938Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14712598.7.7.929
Keywords
dendritic cells; immune dysfunction; immune therapy; sepsis
Funding
- NIGMS NIH HHS [R01 GM46354] Funding Source: Medline
Ask authors/readers for more resources
Sepsis represents a complex clinical syndrome of significant morbidity and mortality. This continues to be the case in intensive care units around the world, despite extensive use of antibiotics, aggressive surgical intervention and optimization of nutritional support. Furthermore, the failure of > 30 anti-inflammatory mediator therapeutic trials implies, beyond the issue of trial design, there remains the necessity to develop a better understanding of the evolving pathophysiology of this syndrome. Studies indicate that the development of marked immune suppression in sepsis is more often associated with morbid outcome. Dendritic cells, a critical immune cell type bridging the innate and adaptive immune response, not only are affected (killed) by the systemic inflammatory response but also contribute to (by impaired function) the development of immune suppression during sepsis. Here the authors attempt to review emerging data indicating the key role dendritic cells may play in sepsis-induced immune suppression. Undoubtedly, a better understanding of the dendritic cell's response during sepsis will be critical to developing novel strategies for fighting this deadly disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available